nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—MT3—breast cancer	0.324	0.696	CbGaD
Prazosin—SLC22A3—Melphalan—breast cancer	0.077	0.234	CbGbCtD
Prazosin—ABCG2—breast cancer	0.0643	0.138	CbGaD
Prazosin—CYP1A1—breast cancer	0.0504	0.108	CbGaD
Prazosin—CYP1A1—Toremifene—breast cancer	0.0375	0.114	CbGbCtD
Prazosin—ABCB1—breast cancer	0.0268	0.0575	CbGaD
Prazosin—SLC22A3—Irinotecan—breast cancer	0.0261	0.0793	CbGbCtD
Prazosin—ABCG2—Tamoxifen—breast cancer	0.0148	0.0452	CbGbCtD
Prazosin—ABCB1—Toremifene—breast cancer	0.0146	0.0446	CbGbCtD
Prazosin—ABCG2—Mitoxantrone—breast cancer	0.0145	0.044	CbGbCtD
Prazosin—SLC22A2—Vinblastine—breast cancer	0.0137	0.0418	CbGbCtD
Prazosin—CYP1A1—Tamoxifen—breast cancer	0.0137	0.0417	CbGbCtD
Prazosin—ABCG2—Paclitaxel—breast cancer	0.0115	0.0351	CbGbCtD
Prazosin—ABCG2—Irinotecan—breast cancer	0.0114	0.0347	CbGbCtD
Prazosin—ABCG2—Fluorouracil—breast cancer	0.0109	0.0333	CbGbCtD
Prazosin—ABCG2—Carboplatin—breast cancer	0.0109	0.0331	CbGbCtD
Prazosin—ABCB1—Lapatinib—breast cancer	0.0107	0.0325	CbGbCtD
Prazosin—ABCG2—Docetaxel—breast cancer	0.00834	0.0254	CbGbCtD
Prazosin—ABCG2—Doxorubicin—breast cancer	0.00622	0.0189	CbGbCtD
Prazosin—ABCG2—Methotrexate—breast cancer	0.00602	0.0183	CbGbCtD
Prazosin—ABCB1—Vinorelbine—breast cancer	0.00592	0.018	CbGbCtD
Prazosin—ABCB1—Tamoxifen—breast cancer	0.00535	0.0163	CbGbCtD
Prazosin—ABCB1—Mitoxantrone—breast cancer	0.00521	0.0159	CbGbCtD
Prazosin—ABCB1—Gemcitabine—breast cancer	0.00461	0.014	CbGbCtD
Prazosin—ABCB1—Paclitaxel—breast cancer	0.00416	0.0127	CbGbCtD
Prazosin—ABCB1—Irinotecan—breast cancer	0.0041	0.0125	CbGbCtD
Prazosin—ABCB1—Vinblastine—breast cancer	0.00365	0.0111	CbGbCtD
Prazosin—ABCB1—Docetaxel—breast cancer	0.00301	0.00916	CbGbCtD
Prazosin—ABCB1—Doxorubicin—breast cancer	0.00224	0.00683	CbGbCtD
Prazosin—ABCB1—Methotrexate—breast cancer	0.00217	0.00662	CbGbCtD
Prazosin—MT3—endocrine gland—breast cancer	0.00084	0.0429	CbGeAlD
Prazosin—KCNH6—uterus—breast cancer	0.000787	0.0402	CbGeAlD
Prazosin—KCNH6—female reproductive system—breast cancer	0.000708	0.0361	CbGeAlD
Prazosin—MT3—lymph node—breast cancer	0.000581	0.0296	CbGeAlD
Prazosin—SLC22A3—nipple—breast cancer	0.000565	0.0288	CbGeAlD
Prazosin—ADRA1D—epithelium—breast cancer	0.000528	0.0269	CbGeAlD
Prazosin—SLC22A3—embryo—breast cancer	0.000466	0.0238	CbGeAlD
Prazosin—KCNH2—nipple—breast cancer	0.000435	0.0222	CbGeAlD
Prazosin—ADRA1D—female reproductive system—breast cancer	0.000392	0.02	CbGeAlD
Prazosin—ORM1—endometrium—breast cancer	0.00039	0.0199	CbGeAlD
Prazosin—Alfuzosin—CYP3A4—breast cancer	0.000371	0.33	CrCbGaD
Prazosin—CYP1A1—nipple—breast cancer	0.000367	0.0187	CbGeAlD
Prazosin—ADRA2A—nipple—breast cancer	0.000342	0.0175	CbGeAlD
Prazosin—SLC22A3—endometrium—breast cancer	0.000341	0.0174	CbGeAlD
Prazosin—ADRA1D—endocrine gland—breast cancer	0.000332	0.0169	CbGeAlD
Prazosin—ORM1—female reproductive system—breast cancer	0.000323	0.0165	CbGeAlD
Prazosin—SLC22A1—adipose tissue—breast cancer	0.000322	0.0164	CbGeAlD
Prazosin—SLC22A3—adipose tissue—breast cancer	0.000308	0.0157	CbGeAlD
Prazosin—ORM1—bone marrow—breast cancer	0.000305	0.0155	CbGeAlD
Prazosin—ADRA1A—epithelium—breast cancer	0.000303	0.0155	CbGeAlD
Prazosin—HTR1D—female reproductive system—breast cancer	0.000293	0.0149	CbGeAlD
Prazosin—SLC22A3—female reproductive system—breast cancer	0.000283	0.0144	CbGeAlD
Prazosin—Doxazosin—CYP2D6—breast cancer	0.000281	0.25	CrCbGaD
Prazosin—SLC22A3—adrenal gland—breast cancer	0.000276	0.0141	CbGeAlD
Prazosin—ORM1—endocrine gland—breast cancer	0.000273	0.0139	CbGeAlD
Prazosin—Terazosin—ABCB1—breast cancer	0.00027	0.24	CrCbGaD
Prazosin—KCNH2—endometrium—breast cancer	0.000263	0.0134	CbGeAlD
Prazosin—SLC22A3—female gonad—breast cancer	0.000257	0.0131	CbGeAlD
Prazosin—SLC22A1—endocrine gland—breast cancer	0.00025	0.0128	CbGeAlD
Prazosin—CYP1A1—epithelium—breast cancer	0.000247	0.0126	CbGeAlD
Prazosin—ADRA1A—adipose tissue—breast cancer	0.000245	0.0125	CbGeAlD
Prazosin—KCNH2—uterus—breast cancer	0.000242	0.0123	CbGeAlD
Prazosin—SLC22A3—endocrine gland—breast cancer	0.000239	0.0122	CbGeAlD
Prazosin—HTR1A—adrenal gland—breast cancer	0.000238	0.0122	CbGeAlD
Prazosin—KCNH2—pituitary gland—breast cancer	0.000238	0.0121	CbGeAlD
Prazosin—CYP1A1—skin of body—breast cancer	0.000235	0.012	CbGeAlD
Prazosin—ABCG2—endometrium—breast cancer	0.000234	0.0119	CbGeAlD
Prazosin—ADRA1A—adrenal gland—breast cancer	0.00022	0.0112	CbGeAlD
Prazosin—KCNH2—female reproductive system—breast cancer	0.000217	0.0111	CbGeAlD
Prazosin—ABCG2—uterus—breast cancer	0.000215	0.011	CbGeAlD
Prazosin—KCNH2—adrenal gland—breast cancer	0.000212	0.0108	CbGeAlD
Prazosin—ABCG2—pituitary gland—breast cancer	0.000211	0.0108	CbGeAlD
Prazosin—ABCG2—adipose tissue—breast cancer	0.00021	0.0107	CbGeAlD
Prazosin—HTR1A—endocrine gland—breast cancer	0.000207	0.0105	CbGeAlD
Prazosin—ADRA2A—endometrium—breast cancer	0.000207	0.0105	CbGeAlD
Prazosin—KCNH2—bone marrow—breast cancer	0.000205	0.0105	CbGeAlD
Prazosin—CYP1A1—uterus—breast cancer	0.000204	0.0104	CbGeAlD
Prazosin—Doxazosin—ABCB1—breast cancer	0.000201	0.179	CrCbGaD
Prazosin—CYP1A1—adipose tissue—breast cancer	0.0002	0.0102	CbGeAlD
Prazosin—KCNH2—female gonad—breast cancer	0.000198	0.0101	CbGeAlD
Prazosin—ADRA1A—endocrine gland—breast cancer	0.000191	0.00972	CbGeAlD
Prazosin—ADRA2A—uterus—breast cancer	0.00019	0.00972	CbGeAlD
Prazosin—ORM1—lymph node—breast cancer	0.000189	0.00963	CbGeAlD
Prazosin—ABCG2—adrenal gland—breast cancer	0.000189	0.00963	CbGeAlD
Prazosin—ADRA2A—pituitary gland—breast cancer	0.000187	0.00954	CbGeAlD
Prazosin—ADRA2A—adipose tissue—breast cancer	0.000186	0.0095	CbGeAlD
Prazosin—KCNH2—endocrine gland—breast cancer	0.000184	0.00939	CbGeAlD
Prazosin—CYP1A1—female reproductive system—breast cancer	0.000184	0.00937	CbGeAlD
Prazosin—ABCG2—bone marrow—breast cancer	0.000183	0.00932	CbGeAlD
Prazosin—ABCG2—female gonad—breast cancer	0.000176	0.00898	CbGeAlD
Prazosin—ADRA2A—female reproductive system—breast cancer	0.000171	0.00873	CbGeAlD
Prazosin—CYP1A1—female gonad—breast cancer	0.000167	0.00852	CbGeAlD
Prazosin—ADRA2A—adrenal gland—breast cancer	0.000167	0.00852	CbGeAlD
Prazosin—SLC22A3—lymph node—breast cancer	0.000165	0.00843	CbGeAlD
Prazosin—ABCB1—embryo—breast cancer	0.000157	0.00803	CbGeAlD
Prazosin—ADRA2A—female gonad—breast cancer	0.000156	0.00795	CbGeAlD
Prazosin—CYP1A1—endocrine gland—breast cancer	0.000155	0.00793	CbGeAlD
Prazosin—ADRA2A—endocrine gland—breast cancer	0.000145	0.00739	CbGeAlD
Prazosin—ABCB1—epithelium—breast cancer	0.000128	0.00655	CbGeAlD
Prazosin—KCNH2—lymph node—breast cancer	0.000127	0.00649	CbGeAlD
Prazosin—ABCB1—endometrium—breast cancer	0.000115	0.00587	CbGeAlD
Prazosin—ABCG2—lymph node—breast cancer	0.000113	0.00577	CbGeAlD
Prazosin—CYP1A1—lymph node—breast cancer	0.000107	0.00548	CbGeAlD
Prazosin—ABCB1—uterus—breast cancer	0.000106	0.00541	CbGeAlD
Prazosin—ABCB1—pituitary gland—breast cancer	0.000104	0.00532	CbGeAlD
Prazosin—ABCB1—adipose tissue—breast cancer	0.000104	0.00529	CbGeAlD
Prazosin—ADRA2A—lymph node—breast cancer	0.0001	0.00511	CbGeAlD
Prazosin—ABCB1—female reproductive system—breast cancer	9.54e-05	0.00487	CbGeAlD
Prazosin—ABCB1—adrenal gland—breast cancer	9.31e-05	0.00475	CbGeAlD
Prazosin—ABCB1—bone marrow—breast cancer	9.01e-05	0.00459	CbGeAlD
Prazosin—ABCB1—female gonad—breast cancer	8.68e-05	0.00443	CbGeAlD
Prazosin—ABCB1—endocrine gland—breast cancer	8.07e-05	0.00412	CbGeAlD
Prazosin—Vomiting—Vinorelbine—breast cancer	7.55e-05	0.000737	CcSEcCtD
Prazosin—Body temperature increased—Gemcitabine—breast cancer	7.54e-05	0.000736	CcSEcCtD
Prazosin—Dizziness—Thiotepa—breast cancer	7.5e-05	0.000732	CcSEcCtD
Prazosin—Rash—Vinorelbine—breast cancer	7.49e-05	0.000731	CcSEcCtD
Prazosin—Dermatitis—Vinorelbine—breast cancer	7.48e-05	0.00073	CcSEcCtD
Prazosin—Ill-defined disorder—Capecitabine—breast cancer	7.45e-05	0.000727	CcSEcCtD
Prazosin—Urticaria—Fluorouracil—breast cancer	7.45e-05	0.000727	CcSEcCtD
Prazosin—Headache—Vinorelbine—breast cancer	7.44e-05	0.000726	CcSEcCtD
Prazosin—Syncope—Docetaxel—breast cancer	7.44e-05	0.000726	CcSEcCtD
Prazosin—Pollakiuria—Epirubicin—breast cancer	7.42e-05	0.000724	CcSEcCtD
Prazosin—Body temperature increased—Fluorouracil—breast cancer	7.42e-05	0.000724	CcSEcCtD
Prazosin—Palpitations—Docetaxel—breast cancer	7.33e-05	0.000715	CcSEcCtD
Prazosin—Loss of consciousness—Docetaxel—breast cancer	7.29e-05	0.000711	CcSEcCtD
Prazosin—Pancreatitis—Doxorubicin—breast cancer	7.29e-05	0.000711	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Paclitaxel—breast cancer	7.28e-05	0.00071	CcSEcCtD
Prazosin—Malaise—Capecitabine—breast cancer	7.24e-05	0.000707	CcSEcCtD
Prazosin—Angina pectoris—Doxorubicin—breast cancer	7.24e-05	0.000706	CcSEcCtD
Prazosin—Insomnia—Paclitaxel—breast cancer	7.23e-05	0.000705	CcSEcCtD
Prazosin—Epistaxis—Methotrexate—breast cancer	7.22e-05	0.000704	CcSEcCtD
Prazosin—Vertigo—Capecitabine—breast cancer	7.22e-05	0.000704	CcSEcCtD
Prazosin—Hypersensitivity—Mitoxantrone—breast cancer	7.22e-05	0.000704	CcSEcCtD
Prazosin—Hypersensitivity—Irinotecan—breast cancer	7.22e-05	0.000704	CcSEcCtD
Prazosin—Vomiting—Thiotepa—breast cancer	7.21e-05	0.000704	CcSEcCtD
Prazosin—Syncope—Capecitabine—breast cancer	7.2e-05	0.000703	CcSEcCtD
Prazosin—Paraesthesia—Paclitaxel—breast cancer	7.17e-05	0.0007	CcSEcCtD
Prazosin—Drowsiness—Epirubicin—breast cancer	7.16e-05	0.000699	CcSEcCtD
Prazosin—Rash—Thiotepa—breast cancer	7.15e-05	0.000698	CcSEcCtD
Prazosin—Dermatitis—Thiotepa—breast cancer	7.15e-05	0.000697	CcSEcCtD
Prazosin—Dyspnoea—Paclitaxel—breast cancer	7.12e-05	0.000695	CcSEcCtD
Prazosin—Headache—Thiotepa—breast cancer	7.11e-05	0.000693	CcSEcCtD
Prazosin—Somnolence—Paclitaxel—breast cancer	7.1e-05	0.000693	CcSEcCtD
Prazosin—Palpitations—Capecitabine—breast cancer	7.1e-05	0.000693	CcSEcCtD
Prazosin—Arthralgia—Docetaxel—breast cancer	7.06e-05	0.000689	CcSEcCtD
Prazosin—Loss of consciousness—Capecitabine—breast cancer	7.06e-05	0.000689	CcSEcCtD
Prazosin—Nausea—Vinorelbine—breast cancer	7.06e-05	0.000688	CcSEcCtD
Prazosin—Asthenia—Mitoxantrone—breast cancer	7.03e-05	0.000686	CcSEcCtD
Prazosin—Asthenia—Irinotecan—breast cancer	7.03e-05	0.000686	CcSEcCtD
Prazosin—Hypersensitivity—Fluorouracil—breast cancer	6.91e-05	0.000674	CcSEcCtD
Prazosin—Dry mouth—Docetaxel—breast cancer	6.91e-05	0.000674	CcSEcCtD
Prazosin—Fatigue—Paclitaxel—breast cancer	6.89e-05	0.000672	CcSEcCtD
Prazosin—Pollakiuria—Doxorubicin—breast cancer	6.87e-05	0.00067	CcSEcCtD
Prazosin—Asthenia—Gemcitabine—breast cancer	6.85e-05	0.000668	CcSEcCtD
Prazosin—Arthralgia—Capecitabine—breast cancer	6.84e-05	0.000667	CcSEcCtD
Prazosin—Constipation—Paclitaxel—breast cancer	6.83e-05	0.000667	CcSEcCtD
Prazosin—Pain—Paclitaxel—breast cancer	6.83e-05	0.000667	CcSEcCtD
Prazosin—Oedema—Docetaxel—breast cancer	6.77e-05	0.000661	CcSEcCtD
Prazosin—Discomfort—Capecitabine—breast cancer	6.76e-05	0.000659	CcSEcCtD
Prazosin—Epistaxis—Epirubicin—breast cancer	6.75e-05	0.000659	CcSEcCtD
Prazosin—Pruritus—Gemcitabine—breast cancer	6.75e-05	0.000659	CcSEcCtD
Prazosin—Nausea—Thiotepa—breast cancer	6.74e-05	0.000657	CcSEcCtD
Prazosin—Diarrhoea—Mitoxantrone—breast cancer	6.7e-05	0.000654	CcSEcCtD
Prazosin—Diarrhoea—Irinotecan—breast cancer	6.7e-05	0.000654	CcSEcCtD
Prazosin—Dry mouth—Capecitabine—breast cancer	6.69e-05	0.000653	CcSEcCtD
Prazosin—Shock—Docetaxel—breast cancer	6.66e-05	0.00065	CcSEcCtD
Prazosin—Pruritus—Fluorouracil—breast cancer	6.64e-05	0.000648	CcSEcCtD
Prazosin—Drowsiness—Doxorubicin—breast cancer	6.63e-05	0.000646	CcSEcCtD
Prazosin—Tachycardia—Docetaxel—breast cancer	6.61e-05	0.000645	CcSEcCtD
Prazosin—Feeling abnormal—Paclitaxel—breast cancer	6.58e-05	0.000642	CcSEcCtD
Prazosin—Oedema—Capecitabine—breast cancer	6.56e-05	0.00064	CcSEcCtD
Prazosin—Bradycardia—Epirubicin—breast cancer	6.54e-05	0.000639	CcSEcCtD
Prazosin—Diarrhoea—Gemcitabine—breast cancer	6.53e-05	0.000637	CcSEcCtD
Prazosin—Dizziness—Irinotecan—breast cancer	6.48e-05	0.000632	CcSEcCtD
Prazosin—Shock—Capecitabine—breast cancer	6.45e-05	0.000629	CcSEcCtD
Prazosin—Diarrhoea—Fluorouracil—breast cancer	6.42e-05	0.000626	CcSEcCtD
Prazosin—Tinnitus—Methotrexate—breast cancer	6.41e-05	0.000625	CcSEcCtD
Prazosin—Tachycardia—Capecitabine—breast cancer	6.4e-05	0.000624	CcSEcCtD
Prazosin—Urticaria—Paclitaxel—breast cancer	6.35e-05	0.000619	CcSEcCtD
Prazosin—Hyperhidrosis—Capecitabine—breast cancer	6.34e-05	0.000618	CcSEcCtD
Prazosin—Body temperature increased—Paclitaxel—breast cancer	6.32e-05	0.000616	CcSEcCtD
Prazosin—Epistaxis—Doxorubicin—breast cancer	6.25e-05	0.00061	CcSEcCtD
Prazosin—Vomiting—Mitoxantrone—breast cancer	6.23e-05	0.000608	CcSEcCtD
Prazosin—Vomiting—Irinotecan—breast cancer	6.23e-05	0.000608	CcSEcCtD
Prazosin—Dizziness—Fluorouracil—breast cancer	6.2e-05	0.000605	CcSEcCtD
Prazosin—Rash—Irinotecan—breast cancer	6.18e-05	0.000603	CcSEcCtD
Prazosin—Rash—Mitoxantrone—breast cancer	6.18e-05	0.000603	CcSEcCtD
Prazosin—Dermatitis—Mitoxantrone—breast cancer	6.17e-05	0.000602	CcSEcCtD
Prazosin—Dermatitis—Irinotecan—breast cancer	6.17e-05	0.000602	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Docetaxel—breast cancer	6.17e-05	0.000602	CcSEcCtD
Prazosin—Headache—Irinotecan—breast cancer	6.14e-05	0.000599	CcSEcCtD
Prazosin—Headache—Mitoxantrone—breast cancer	6.14e-05	0.000599	CcSEcCtD
Prazosin—Insomnia—Docetaxel—breast cancer	6.12e-05	0.000598	CcSEcCtD
Prazosin—Paraesthesia—Docetaxel—breast cancer	6.08e-05	0.000593	CcSEcCtD
Prazosin—Alopecia—Methotrexate—breast cancer	6.07e-05	0.000592	CcSEcCtD
Prazosin—Vomiting—Gemcitabine—breast cancer	6.07e-05	0.000592	CcSEcCtD
Prazosin—Bradycardia—Doxorubicin—breast cancer	6.06e-05	0.000591	CcSEcCtD
Prazosin—Dyspnoea—Docetaxel—breast cancer	6.04e-05	0.000589	CcSEcCtD
Prazosin—Somnolence—Docetaxel—breast cancer	6.02e-05	0.000587	CcSEcCtD
Prazosin—Rash—Gemcitabine—breast cancer	6.02e-05	0.000587	CcSEcCtD
Prazosin—Dermatitis—Gemcitabine—breast cancer	6.01e-05	0.000586	CcSEcCtD
Prazosin—Tinnitus—Epirubicin—breast cancer	5.99e-05	0.000585	CcSEcCtD
Prazosin—Headache—Gemcitabine—breast cancer	5.98e-05	0.000583	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Capecitabine—breast cancer	5.97e-05	0.000583	CcSEcCtD
Prazosin—Flushing—Epirubicin—breast cancer	5.97e-05	0.000582	CcSEcCtD
Prazosin—Vomiting—Fluorouracil—breast cancer	5.97e-05	0.000582	CcSEcCtD
Prazosin—Insomnia—Capecitabine—breast cancer	5.93e-05	0.000579	CcSEcCtD
Prazosin—Rash—Fluorouracil—breast cancer	5.92e-05	0.000577	CcSEcCtD
Prazosin—Dermatitis—Fluorouracil—breast cancer	5.91e-05	0.000577	CcSEcCtD
Prazosin—Paraesthesia—Capecitabine—breast cancer	5.89e-05	0.000574	CcSEcCtD
Prazosin—Hypersensitivity—Paclitaxel—breast cancer	5.89e-05	0.000574	CcSEcCtD
Prazosin—Headache—Fluorouracil—breast cancer	5.88e-05	0.000573	CcSEcCtD
Prazosin—Dyspnoea—Capecitabine—breast cancer	5.85e-05	0.00057	CcSEcCtD
Prazosin—Fatigue—Docetaxel—breast cancer	5.84e-05	0.00057	CcSEcCtD
Prazosin—Nausea—Irinotecan—breast cancer	5.82e-05	0.000568	CcSEcCtD
Prazosin—Nausea—Mitoxantrone—breast cancer	5.82e-05	0.000568	CcSEcCtD
Prazosin—Pain—Docetaxel—breast cancer	5.79e-05	0.000565	CcSEcCtD
Prazosin—Constipation—Docetaxel—breast cancer	5.79e-05	0.000565	CcSEcCtD
Prazosin—Asthenia—Paclitaxel—breast cancer	5.73e-05	0.000559	CcSEcCtD
Prazosin—Alopecia—Epirubicin—breast cancer	5.68e-05	0.000554	CcSEcCtD
Prazosin—Nausea—Gemcitabine—breast cancer	5.67e-05	0.000553	CcSEcCtD
Prazosin—Fatigue—Capecitabine—breast cancer	5.65e-05	0.000551	CcSEcCtD
Prazosin—Pruritus—Paclitaxel—breast cancer	5.65e-05	0.000551	CcSEcCtD
Prazosin—Vision blurred—Methotrexate—breast cancer	5.64e-05	0.00055	CcSEcCtD
Prazosin—Pain—Capecitabine—breast cancer	5.61e-05	0.000547	CcSEcCtD
Prazosin—Constipation—Capecitabine—breast cancer	5.61e-05	0.000547	CcSEcCtD
Prazosin—ABCB1—lymph node—breast cancer	5.58e-05	0.00285	CbGeAlD
Prazosin—Feeling abnormal—Docetaxel—breast cancer	5.58e-05	0.000544	CcSEcCtD
Prazosin—Nausea—Fluorouracil—breast cancer	5.57e-05	0.000544	CcSEcCtD
Prazosin—Ill-defined disorder—Methotrexate—breast cancer	5.55e-05	0.000541	CcSEcCtD
Prazosin—Tinnitus—Doxorubicin—breast cancer	5.55e-05	0.000541	CcSEcCtD
Prazosin—Flushing—Doxorubicin—breast cancer	5.52e-05	0.000539	CcSEcCtD
Prazosin—Tension—Epirubicin—breast cancer	5.49e-05	0.000536	CcSEcCtD
Prazosin—Diarrhoea—Paclitaxel—breast cancer	5.47e-05	0.000533	CcSEcCtD
Prazosin—Nervousness—Epirubicin—breast cancer	5.44e-05	0.00053	CcSEcCtD
Prazosin—Feeling abnormal—Capecitabine—breast cancer	5.4e-05	0.000527	CcSEcCtD
Prazosin—Malaise—Methotrexate—breast cancer	5.39e-05	0.000526	CcSEcCtD
Prazosin—Vertigo—Methotrexate—breast cancer	5.37e-05	0.000524	CcSEcCtD
Prazosin—Body temperature increased—Docetaxel—breast cancer	5.35e-05	0.000522	CcSEcCtD
Prazosin—Dizziness—Paclitaxel—breast cancer	5.28e-05	0.000515	CcSEcCtD
Prazosin—Vision blurred—Epirubicin—breast cancer	5.27e-05	0.000515	CcSEcCtD
Prazosin—Alopecia—Doxorubicin—breast cancer	5.26e-05	0.000513	CcSEcCtD
Prazosin—Urticaria—Capecitabine—breast cancer	5.21e-05	0.000508	CcSEcCtD
Prazosin—Ill-defined disorder—Epirubicin—breast cancer	5.19e-05	0.000507	CcSEcCtD
Prazosin—Body temperature increased—Capecitabine—breast cancer	5.18e-05	0.000506	CcSEcCtD
Prazosin—Arthralgia—Methotrexate—breast cancer	5.09e-05	0.000497	CcSEcCtD
Prazosin—Tension—Doxorubicin—breast cancer	5.08e-05	0.000496	CcSEcCtD
Prazosin—Vomiting—Paclitaxel—breast cancer	5.08e-05	0.000496	CcSEcCtD
Prazosin—Malaise—Epirubicin—breast cancer	5.05e-05	0.000492	CcSEcCtD
Prazosin—Rash—Paclitaxel—breast cancer	5.04e-05	0.000491	CcSEcCtD
Prazosin—Dermatitis—Paclitaxel—breast cancer	5.03e-05	0.000491	CcSEcCtD
Prazosin—Discomfort—Methotrexate—breast cancer	5.03e-05	0.000491	CcSEcCtD
Prazosin—Nervousness—Doxorubicin—breast cancer	5.03e-05	0.000491	CcSEcCtD
Prazosin—Vertigo—Epirubicin—breast cancer	5.03e-05	0.000491	CcSEcCtD
Prazosin—Syncope—Epirubicin—breast cancer	5.02e-05	0.00049	CcSEcCtD
Prazosin—Headache—Paclitaxel—breast cancer	5e-05	0.000488	CcSEcCtD
Prazosin—Hypersensitivity—Docetaxel—breast cancer	4.99e-05	0.000487	CcSEcCtD
Prazosin—Palpitations—Epirubicin—breast cancer	4.95e-05	0.000483	CcSEcCtD
Prazosin—Loss of consciousness—Epirubicin—breast cancer	4.92e-05	0.00048	CcSEcCtD
Prazosin—Vision blurred—Doxorubicin—breast cancer	4.88e-05	0.000476	CcSEcCtD
Prazosin—Asthenia—Docetaxel—breast cancer	4.86e-05	0.000474	CcSEcCtD
Prazosin—Hypersensitivity—Capecitabine—breast cancer	4.83e-05	0.000471	CcSEcCtD
Prazosin—Ill-defined disorder—Doxorubicin—breast cancer	4.8e-05	0.000469	CcSEcCtD
Prazosin—Pruritus—Docetaxel—breast cancer	4.79e-05	0.000467	CcSEcCtD
Prazosin—Arthralgia—Epirubicin—breast cancer	4.76e-05	0.000465	CcSEcCtD
Prazosin—Nausea—Paclitaxel—breast cancer	4.75e-05	0.000463	CcSEcCtD
Prazosin—Hyperhidrosis—Methotrexate—breast cancer	4.72e-05	0.00046	CcSEcCtD
Prazosin—Discomfort—Epirubicin—breast cancer	4.71e-05	0.000459	CcSEcCtD
Prazosin—Asthenia—Capecitabine—breast cancer	4.7e-05	0.000459	CcSEcCtD
Prazosin—Malaise—Doxorubicin—breast cancer	4.67e-05	0.000456	CcSEcCtD
Prazosin—Dry mouth—Epirubicin—breast cancer	4.66e-05	0.000455	CcSEcCtD
Prazosin—Vertigo—Doxorubicin—breast cancer	4.65e-05	0.000454	CcSEcCtD
Prazosin—Syncope—Doxorubicin—breast cancer	4.64e-05	0.000453	CcSEcCtD
Prazosin—Pruritus—Capecitabine—breast cancer	4.64e-05	0.000453	CcSEcCtD
Prazosin—Diarrhoea—Docetaxel—breast cancer	4.63e-05	0.000452	CcSEcCtD
Prazosin—Palpitations—Doxorubicin—breast cancer	4.58e-05	0.000446	CcSEcCtD
Prazosin—Oedema—Epirubicin—breast cancer	4.57e-05	0.000446	CcSEcCtD
Prazosin—Loss of consciousness—Doxorubicin—breast cancer	4.55e-05	0.000444	CcSEcCtD
Prazosin—Shock—Epirubicin—breast cancer	4.49e-05	0.000438	CcSEcCtD
Prazosin—Diarrhoea—Capecitabine—breast cancer	4.49e-05	0.000438	CcSEcCtD
Prazosin—Dizziness—Docetaxel—breast cancer	4.48e-05	0.000437	CcSEcCtD
Prazosin—Tachycardia—Epirubicin—breast cancer	4.46e-05	0.000435	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Methotrexate—breast cancer	4.45e-05	0.000434	CcSEcCtD
Prazosin—Hyperhidrosis—Epirubicin—breast cancer	4.42e-05	0.000431	CcSEcCtD
Prazosin—Insomnia—Methotrexate—breast cancer	4.41e-05	0.000431	CcSEcCtD
Prazosin—Arthralgia—Doxorubicin—breast cancer	4.41e-05	0.00043	CcSEcCtD
Prazosin—Paraesthesia—Methotrexate—breast cancer	4.38e-05	0.000428	CcSEcCtD
Prazosin—Discomfort—Doxorubicin—breast cancer	4.36e-05	0.000425	CcSEcCtD
Prazosin—Dyspnoea—Methotrexate—breast cancer	4.35e-05	0.000425	CcSEcCtD
Prazosin—Somnolence—Methotrexate—breast cancer	4.34e-05	0.000423	CcSEcCtD
Prazosin—Dizziness—Capecitabine—breast cancer	4.34e-05	0.000423	CcSEcCtD
Prazosin—Dry mouth—Doxorubicin—breast cancer	4.31e-05	0.000421	CcSEcCtD
Prazosin—Vomiting—Docetaxel—breast cancer	4.31e-05	0.00042	CcSEcCtD
Prazosin—Rash—Docetaxel—breast cancer	4.27e-05	0.000417	CcSEcCtD
Prazosin—Dermatitis—Docetaxel—breast cancer	4.27e-05	0.000416	CcSEcCtD
Prazosin—Headache—Docetaxel—breast cancer	4.24e-05	0.000414	CcSEcCtD
Prazosin—Oedema—Doxorubicin—breast cancer	4.23e-05	0.000412	CcSEcCtD
Prazosin—Fatigue—Methotrexate—breast cancer	4.21e-05	0.000411	CcSEcCtD
Prazosin—Pain—Methotrexate—breast cancer	4.17e-05	0.000407	CcSEcCtD
Prazosin—Vomiting—Capecitabine—breast cancer	4.17e-05	0.000407	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Epirubicin—breast cancer	4.16e-05	0.000406	CcSEcCtD
Prazosin—Shock—Doxorubicin—breast cancer	4.16e-05	0.000406	CcSEcCtD
Prazosin—Rash—Capecitabine—breast cancer	4.13e-05	0.000403	CcSEcCtD
Prazosin—Insomnia—Epirubicin—breast cancer	4.13e-05	0.000403	CcSEcCtD
Prazosin—Dermatitis—Capecitabine—breast cancer	4.13e-05	0.000403	CcSEcCtD
Prazosin—Tachycardia—Doxorubicin—breast cancer	4.12e-05	0.000402	CcSEcCtD
Prazosin—Headache—Capecitabine—breast cancer	4.11e-05	0.000401	CcSEcCtD
Prazosin—Paraesthesia—Epirubicin—breast cancer	4.1e-05	0.0004	CcSEcCtD
Prazosin—Hyperhidrosis—Doxorubicin—breast cancer	4.09e-05	0.000399	CcSEcCtD
Prazosin—Dyspnoea—Epirubicin—breast cancer	4.07e-05	0.000397	CcSEcCtD
Prazosin—Somnolence—Epirubicin—breast cancer	4.06e-05	0.000396	CcSEcCtD
Prazosin—Nausea—Docetaxel—breast cancer	4.02e-05	0.000392	CcSEcCtD
Prazosin—Feeling abnormal—Methotrexate—breast cancer	4.02e-05	0.000392	CcSEcCtD
Prazosin—Fatigue—Epirubicin—breast cancer	3.94e-05	0.000384	CcSEcCtD
Prazosin—Pain—Epirubicin—breast cancer	3.91e-05	0.000381	CcSEcCtD
Prazosin—Constipation—Epirubicin—breast cancer	3.91e-05	0.000381	CcSEcCtD
Prazosin—Nausea—Capecitabine—breast cancer	3.89e-05	0.00038	CcSEcCtD
Prazosin—Urticaria—Methotrexate—breast cancer	3.88e-05	0.000378	CcSEcCtD
Prazosin—Body temperature increased—Methotrexate—breast cancer	3.86e-05	0.000376	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.85e-05	0.000376	CcSEcCtD
Prazosin—Insomnia—Doxorubicin—breast cancer	3.82e-05	0.000373	CcSEcCtD
Prazosin—Paraesthesia—Doxorubicin—breast cancer	3.79e-05	0.00037	CcSEcCtD
Prazosin—Dyspnoea—Doxorubicin—breast cancer	3.77e-05	0.000368	CcSEcCtD
Prazosin—Feeling abnormal—Epirubicin—breast cancer	3.76e-05	0.000367	CcSEcCtD
Prazosin—Somnolence—Doxorubicin—breast cancer	3.76e-05	0.000367	CcSEcCtD
Prazosin—Fatigue—Doxorubicin—breast cancer	3.64e-05	0.000355	CcSEcCtD
Prazosin—Urticaria—Epirubicin—breast cancer	3.63e-05	0.000354	CcSEcCtD
Prazosin—Constipation—Doxorubicin—breast cancer	3.61e-05	0.000353	CcSEcCtD
Prazosin—Pain—Doxorubicin—breast cancer	3.61e-05	0.000353	CcSEcCtD
Prazosin—Body temperature increased—Epirubicin—breast cancer	3.61e-05	0.000352	CcSEcCtD
Prazosin—Hypersensitivity—Methotrexate—breast cancer	3.6e-05	0.000351	CcSEcCtD
Prazosin—Asthenia—Methotrexate—breast cancer	3.5e-05	0.000342	CcSEcCtD
Prazosin—Feeling abnormal—Doxorubicin—breast cancer	3.48e-05	0.00034	CcSEcCtD
Prazosin—Pruritus—Methotrexate—breast cancer	3.45e-05	0.000337	CcSEcCtD
Prazosin—Hypersensitivity—Epirubicin—breast cancer	3.37e-05	0.000328	CcSEcCtD
Prazosin—Urticaria—Doxorubicin—breast cancer	3.36e-05	0.000328	CcSEcCtD
Prazosin—Body temperature increased—Doxorubicin—breast cancer	3.34e-05	0.000326	CcSEcCtD
Prazosin—Diarrhoea—Methotrexate—breast cancer	3.34e-05	0.000326	CcSEcCtD
Prazosin—Asthenia—Epirubicin—breast cancer	3.28e-05	0.00032	CcSEcCtD
Prazosin—Pruritus—Epirubicin—breast cancer	3.23e-05	0.000315	CcSEcCtD
Prazosin—Dizziness—Methotrexate—breast cancer	3.23e-05	0.000315	CcSEcCtD
Prazosin—Diarrhoea—Epirubicin—breast cancer	3.13e-05	0.000305	CcSEcCtD
Prazosin—Hypersensitivity—Doxorubicin—breast cancer	3.11e-05	0.000304	CcSEcCtD
Prazosin—Vomiting—Methotrexate—breast cancer	3.1e-05	0.000303	CcSEcCtD
Prazosin—Rash—Methotrexate—breast cancer	3.08e-05	0.0003	CcSEcCtD
Prazosin—Dermatitis—Methotrexate—breast cancer	3.07e-05	0.0003	CcSEcCtD
Prazosin—Headache—Methotrexate—breast cancer	3.06e-05	0.000298	CcSEcCtD
Prazosin—Asthenia—Doxorubicin—breast cancer	3.03e-05	0.000296	CcSEcCtD
Prazosin—Dizziness—Epirubicin—breast cancer	3.02e-05	0.000295	CcSEcCtD
Prazosin—Pruritus—Doxorubicin—breast cancer	2.99e-05	0.000292	CcSEcCtD
Prazosin—Vomiting—Epirubicin—breast cancer	2.9e-05	0.000283	CcSEcCtD
Prazosin—Nausea—Methotrexate—breast cancer	2.9e-05	0.000283	CcSEcCtD
Prazosin—Diarrhoea—Doxorubicin—breast cancer	2.89e-05	0.000282	CcSEcCtD
Prazosin—Rash—Epirubicin—breast cancer	2.88e-05	0.000281	CcSEcCtD
Prazosin—Dermatitis—Epirubicin—breast cancer	2.88e-05	0.000281	CcSEcCtD
Prazosin—Headache—Epirubicin—breast cancer	2.86e-05	0.000279	CcSEcCtD
Prazosin—Dizziness—Doxorubicin—breast cancer	2.79e-05	0.000273	CcSEcCtD
Prazosin—Nausea—Epirubicin—breast cancer	2.71e-05	0.000265	CcSEcCtD
Prazosin—Vomiting—Doxorubicin—breast cancer	2.69e-05	0.000262	CcSEcCtD
Prazosin—Rash—Doxorubicin—breast cancer	2.66e-05	0.00026	CcSEcCtD
Prazosin—Dermatitis—Doxorubicin—breast cancer	2.66e-05	0.00026	CcSEcCtD
Prazosin—Headache—Doxorubicin—breast cancer	2.65e-05	0.000258	CcSEcCtD
Prazosin—Nausea—Doxorubicin—breast cancer	2.51e-05	0.000245	CcSEcCtD
Prazosin—ADRA2A—Signaling Pathways—KIT—breast cancer	1.61e-06	1.95e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—APC—breast cancer	1.61e-06	1.95e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—JUN—breast cancer	1.61e-06	1.95e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—RAF1—breast cancer	1.61e-06	1.94e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—RELA—breast cancer	1.6e-06	1.94e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—NOS3—breast cancer	1.6e-06	1.93e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CTNNB1—breast cancer	1.59e-06	1.93e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGF—breast cancer	1.59e-06	1.93e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—ERBB2—breast cancer	1.59e-06	1.92e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IGF1—breast cancer	1.58e-06	1.92e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—AKT2—breast cancer	1.58e-06	1.92e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—MTHFR—breast cancer	1.58e-06	1.92e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—EGFR—breast cancer	1.58e-06	1.91e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MTOR—breast cancer	1.57e-06	1.9e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CB—breast cancer	1.57e-06	1.9e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MMP9—breast cancer	1.56e-06	1.89e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CXCL8—breast cancer	1.56e-06	1.89e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CDKN1A—breast cancer	1.56e-06	1.89e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PTEN—breast cancer	1.55e-06	1.88e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK3—breast cancer	1.55e-06	1.88e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—HRAS—breast cancer	1.55e-06	1.88e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—PIK3CA—breast cancer	1.54e-06	1.87e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	1.54e-06	1.87e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MDM2—breast cancer	1.53e-06	1.86e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—RAF1—breast cancer	1.53e-06	1.85e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CDKN1B—breast cancer	1.52e-06	1.85e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—RELA—breast cancer	1.52e-06	1.84e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	1.52e-06	1.84e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK8—breast cancer	1.52e-06	1.84e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—AKT1—breast cancer	1.52e-06	1.84e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—ERBB2—breast cancer	1.51e-06	1.83e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—BRAF—breast cancer	1.51e-06	1.83e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MYC—breast cancer	1.51e-06	1.83e-05	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—AKT1—breast cancer	1.51e-06	1.83e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	1.51e-06	1.83e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CXCL8—breast cancer	1.51e-06	1.82e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TGFB1—breast cancer	1.51e-06	1.82e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	1.5e-06	1.82e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTEN—breast cancer	1.5e-06	1.82e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—HRAS—breast cancer	1.5e-06	1.81e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CASP3—breast cancer	1.49e-06	1.81e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CB—breast cancer	1.49e-06	1.81e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MTOR—breast cancer	1.49e-06	1.81e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL2—breast cancer	1.49e-06	1.81e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—KRAS—breast cancer	1.49e-06	1.8e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—IL6—breast cancer	1.48e-06	1.8e-05	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—AKT1—breast cancer	1.48e-06	1.79e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—EGFR—breast cancer	1.48e-06	1.79e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CB—breast cancer	1.47e-06	1.78e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IGF1—breast cancer	1.47e-06	1.78e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—AKT2—breast cancer	1.47e-06	1.78e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CDKN1B—breast cancer	1.47e-06	1.78e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—EGFR—breast cancer	1.46e-06	1.77e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CD—breast cancer	1.46e-06	1.77e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTGS2—breast cancer	1.46e-06	1.77e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CAV1—breast cancer	1.46e-06	1.77e-05	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—AKT1—breast cancer	1.46e-06	1.76e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CCND1—breast cancer	1.45e-06	1.76e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—JUN—breast cancer	1.45e-06	1.76e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—ALB—breast cancer	1.44e-06	1.75e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CASP3—breast cancer	1.44e-06	1.75e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—SRC—breast cancer	1.44e-06	1.75e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CTNNB1—breast cancer	1.44e-06	1.74e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL2—breast cancer	1.44e-06	1.74e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NOS3—breast cancer	1.44e-06	1.74e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CXCL8—breast cancer	1.43e-06	1.74e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—IL6—breast cancer	1.43e-06	1.74e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—HRAS—breast cancer	1.43e-06	1.73e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	1.41e-06	1.71e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MMP9—breast cancer	1.41e-06	1.71e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CDKN1A—breast cancer	1.41e-06	1.7e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—VEGFA—breast cancer	1.4e-06	1.7e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CCND1—breast cancer	1.4e-06	1.7e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PTEN—breast cancer	1.4e-06	1.7e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CDKN1B—breast cancer	1.4e-06	1.7e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—JUN—breast cancer	1.4e-06	1.7e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	1.4e-06	1.7e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	1.4e-06	1.69e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—KRAS—breast cancer	1.39e-06	1.69e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—STAT3—breast cancer	1.39e-06	1.68e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CTNNB1—breast cancer	1.39e-06	1.68e-05	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—AKT1—breast cancer	1.39e-06	1.68e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—KRAS—breast cancer	1.38e-06	1.68e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—NOS3—breast cancer	1.38e-06	1.67e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CASP3—breast cancer	1.37e-06	1.66e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK8—breast cancer	1.37e-06	1.66e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL2—breast cancer	1.37e-06	1.66e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—AKT1—breast cancer	1.37e-06	1.66e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	1.37e-06	1.66e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—IL6—breast cancer	1.36e-06	1.65e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MDM2—breast cancer	1.36e-06	1.65e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MMP9—breast cancer	1.36e-06	1.65e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—RAF1—breast cancer	1.36e-06	1.65e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CDKN1A—breast cancer	1.36e-06	1.64e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PTEN—breast cancer	1.35e-06	1.64e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—RELA—breast cancer	1.35e-06	1.64e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—ERBB2—breast cancer	1.34e-06	1.63e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CCND1—breast cancer	1.34e-06	1.62e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NOS3—breast cancer	1.33e-06	1.62e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—JUN—breast cancer	1.33e-06	1.62e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CG—breast cancer	1.33e-06	1.61e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK3—breast cancer	1.33e-06	1.61e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MTOR—breast cancer	1.33e-06	1.61e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	1.33e-06	1.61e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK8—breast cancer	1.33e-06	1.61e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CTNNB1—breast cancer	1.32e-06	1.6e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—AKT1—breast cancer	1.32e-06	1.6e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—SRC—breast cancer	1.3e-06	1.58e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MMP9—breast cancer	1.3e-06	1.57e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CDKN1A—breast cancer	1.29e-06	1.57e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MYC—breast cancer	1.29e-06	1.56e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PTEN—breast cancer	1.29e-06	1.56e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TGFB1—breast cancer	1.29e-06	1.56e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—PIK3CA—breast cancer	1.28e-06	1.55e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CB—breast cancer	1.28e-06	1.55e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CXCL8—breast cancer	1.27e-06	1.54e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTEN—breast cancer	1.27e-06	1.54e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	1.27e-06	1.54e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—VEGFA—breast cancer	1.27e-06	1.54e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MDM2—breast cancer	1.27e-06	1.53e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—HRAS—breast cancer	1.27e-06	1.53e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTGS2—breast cancer	1.26e-06	1.53e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—EGFR—breast cancer	1.26e-06	1.53e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK8—breast cancer	1.26e-06	1.53e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—RAF1—breast cancer	1.26e-06	1.53e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—AKT1—breast cancer	1.26e-06	1.52e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—RELA—breast cancer	1.26e-06	1.52e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—SRC—breast cancer	1.26e-06	1.52e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—STAT3—breast cancer	1.25e-06	1.52e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ERBB2—breast cancer	1.25e-06	1.51e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	1.24e-06	1.51e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TP53—breast cancer	1.24e-06	1.5e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MTOR—breast cancer	1.23e-06	1.49e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	1.23e-06	1.49e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	1.23e-06	1.49e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—VEGFA—breast cancer	1.22e-06	1.48e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CASP3—breast cancer	1.22e-06	1.48e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL2—breast cancer	1.22e-06	1.48e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—IL6—breast cancer	1.21e-06	1.47e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—STAT3—breast cancer	1.21e-06	1.47e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK3—breast cancer	1.2e-06	1.45e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—SRC—breast cancer	1.2e-06	1.45e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KRAS—breast cancer	1.19e-06	1.45e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CCND1—breast cancer	1.19e-06	1.44e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—HRAS—breast cancer	1.19e-06	1.44e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—JUN—breast cancer	1.18e-06	1.44e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CXCL8—breast cancer	1.18e-06	1.43e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—HRAS—breast cancer	1.18e-06	1.42e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	1.18e-06	1.42e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CD—breast cancer	1.17e-06	1.42e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MYC—breast cancer	1.17e-06	1.41e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—VEGFA—breast cancer	1.17e-06	1.41e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TGFB1—breast cancer	1.16e-06	1.41e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK3—breast cancer	1.16e-06	1.4e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	1.16e-06	1.4e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—ALB—breast cancer	1.15e-06	1.4e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—STAT3—breast cancer	1.15e-06	1.4e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MMP9—breast cancer	1.15e-06	1.4e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PIK3CA—breast cancer	1.15e-06	1.39e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	1.15e-06	1.39e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PTEN—breast cancer	1.15e-06	1.39e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	1.14e-06	1.39e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—EGFR—breast cancer	1.14e-06	1.38e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PIK3CA—breast cancer	1.14e-06	1.38e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IL6—breast cancer	1.13e-06	1.37e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CASP3—breast cancer	1.13e-06	1.37e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL2—breast cancer	1.13e-06	1.37e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—IL6—breast cancer	1.13e-06	1.36e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MYC—breast cancer	1.13e-06	1.36e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TGFB1—breast cancer	1.12e-06	1.36e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK8—breast cancer	1.12e-06	1.36e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—AKT1—breast cancer	1.12e-06	1.35e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—NOS3—breast cancer	1.1e-06	1.34e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCND1—breast cancer	1.1e-06	1.34e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTEN—breast cancer	1.1e-06	1.34e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK3—breast cancer	1.1e-06	1.34e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—EGFR—breast cancer	1.1e-06	1.33e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—JUN—breast cancer	1.1e-06	1.33e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PIK3CA—breast cancer	1.1e-06	1.33e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	1.09e-06	1.32e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KRAS—breast cancer	1.08e-06	1.31e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MYC—breast cancer	1.07e-06	1.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MMP9—breast cancer	1.07e-06	1.3e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TGFB1—breast cancer	1.07e-06	1.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	1.07e-06	1.29e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTEN—breast cancer	1.06e-06	1.29e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—SRC—breast cancer	1.06e-06	1.29e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TP53—breast cancer	1.06e-06	1.28e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CA—breast cancer	1.06e-06	1.28e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EGFR—breast cancer	1.05e-06	1.27e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—AKT1—breast cancer	1.05e-06	1.27e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK8—breast cancer	1.04e-06	1.26e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KRAS—breast cancer	1.04e-06	1.26e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—AKT1—breast cancer	1.04e-06	1.26e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—VEGFA—breast cancer	1.03e-06	1.25e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—STAT3—breast cancer	1.02e-06	1.24e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CB—breast cancer	1.02e-06	1.23e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—HRAS—breast cancer	1.01e-06	1.23e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTGS2—breast cancer	1.01e-06	1.22e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KRAS—breast cancer	9.91e-07	1.2e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	9.9e-07	1.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—SRC—breast cancer	9.87e-07	1.2e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK3—breast cancer	9.79e-07	1.19e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL6—breast cancer	9.71e-07	1.18e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—VEGFA—breast cancer	9.62e-07	1.16e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TP53—breast cancer	9.58e-07	1.16e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CA—breast cancer	9.56e-07	1.16e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MYC—breast cancer	9.52e-07	1.15e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—STAT3—breast cancer	9.52e-07	1.15e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TGFB1—breast cancer	9.5e-07	1.15e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—AKT1—breast cancer	9.39e-07	1.14e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EGFR—breast cancer	9.31e-07	1.13e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—AKT1—breast cancer	9.29e-07	1.13e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TP53—breast cancer	9.24e-07	1.12e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—HRAS—breast cancer	9.16e-07	1.11e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	9.1e-07	1.1e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK3—breast cancer	9.1e-07	1.1e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CA—breast cancer	8.98e-07	1.09e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—AKT1—breast cancer	8.96e-07	1.09e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MYC—breast cancer	8.85e-07	1.07e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—HRAS—breast cancer	8.84e-07	1.07e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TGFB1—breast cancer	8.83e-07	1.07e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTEN—breast cancer	8.8e-07	1.07e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TP53—breast cancer	8.8e-07	1.07e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KRAS—breast cancer	8.8e-07	1.07e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL6—breast cancer	8.77e-07	1.06e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—AKT1—breast cancer	8.66e-07	1.05e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGFR—breast cancer	8.65e-07	1.05e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL6—breast cancer	8.46e-07	1.03e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—HRAS—breast cancer	8.42e-07	1.02e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KRAS—breast cancer	8.18e-07	9.9e-06	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—AKT1—breast cancer	8.09e-07	9.8e-06	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	8.08e-07	9.79e-06	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL6—breast cancer	8.06e-07	9.76e-06	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TP53—breast cancer	7.82e-07	9.47e-06	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—AKT1—breast cancer	7.81e-07	9.46e-06	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CA—breast cancer	7.78e-07	9.42e-06	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	7.51e-07	9.1e-06	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—HRAS—breast cancer	7.48e-07	9.06e-06	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—AKT1—breast cancer	7.43e-07	9.01e-06	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—AKT1—breast cancer	7.34e-07	8.89e-06	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TP53—breast cancer	7.27e-07	8.8e-06	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6—breast cancer	7.16e-07	8.67e-06	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—HRAS—breast cancer	6.95e-07	8.42e-06	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6—breast cancer	6.65e-07	8.06e-06	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—AKT1—breast cancer	6.6e-07	8e-06	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—AKT1—breast cancer	6.35e-07	7.7e-06	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CA—breast cancer	6.21e-07	7.52e-06	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—AKT1—breast cancer	6.14e-07	7.43e-06	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—AKT1—breast cancer	5.07e-07	6.15e-06	CbGpPWpGaD
